Eli Lilly and Company was given the President's Award by the National Hispanic Council on Aging (NHCOA) at its annual conference in Washington, D.C.
Lilly has developed a successful partnership with the NHCOA to address specific issues facing the aging Hispanic community, such as disparities that exist in the diagnosis of chronic disease.
"The National Hispanic Council on Aging's leadership is proud to honor Lilly with the 2010 President's Award, recognizing the company's commitment to improving the wellbeing of its target audience - especially older adults," said Dr. Yanira Cruz, president & CEO of the NHCOA. "Lilly's philanthropic commitment should serve as an example in the pharmaceutical industry. We applaud Lilly's innovation in addressing key health issues impacting older adults such as diabetes, mental health and Alzheimer's disease."
As part of Lilly's commitment to overcoming health disparities, the company is working to increase Hispanic representation in clinical trials. In the United States, minority populations have historically and consistently been under-represented in clinical trials, which evaluate the safety and efficacy of new medicines and treatments. As part of Lilly's clinical diversity strategy, Lilly is identifying and investing in new relationships with clinical investigators who are likely to treat more diverse patients. As a result, more than 83 new clinical trial sites have been introduced in communities of color since May 2008.
Currently, Lilly and NHCOA are working together to develop initiatives designed to promote diabetes prevention and improve diabetes management among Hispanic older adults and their families through the development of culturally--and linguistically--appropriate and age-sensitive educational efforts. This program aims to reduce the significant disparities that exist between Hispanic and non-Hispanic adults in the United States.
"Lilly and the Council both see the value of promoting better health for our older citizens, and we're pleased that our work has been recognized with this award," said Shaun Hawkins, chief diversity officer at Lilly. "Our commitment to engage, educate and empower patients to take control of their own health becomes even more important when we are working with populations that do not have access to the resources they need to become healthier. Our partnership with NHCOA helps make that connection for patients."
Additional outreach initiatives are conducted by the Organization of Latinos at Lilly, or OLA, an internal employee group. OLA diversity initiatives impact the community, the company and its members by actively supporting the Hispanic/Latino community. For example, OLA members participate in Project Stepping Stone, a community event for Latino high school students from Indiana who are interested in attending college. OLA members also contribute annually to the Hispanic Scholarship Fund organized by USA Funds to help Latino youth access and afford a college education.
Monday, October 4, 2010
GSK provides update on Herpevac trial for women evaluating Simplirix™ (Herpes Simplex Vaccine)
GlaxoSmithKline (GSK) has made the decision not to pursue further worldwide development of Simplirix™ (Herpes Simplex Vaccine), an experimental vaccine intended to prevent genital herpes disease in women.
The decision was made following receipt of the results of the Herpevac Trial for Women, a Phase III trial evaluating efficacy of Simplirix™, which was conducted collaboratively with the US National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH).
The trial began in 2002 and 8,323 women ages 18-30 were vaccinated at 50 sites in the United States and Canada. An assessment of the final trial results showed that the vaccine had an acceptable safety profile, but the primary trial endpoint, prevention of genital herpes disease, was not met. GSK and NIH continue to evaluate data from the trial and plan to present details of the analysis in the near future in an appropriate scientific forum.
Gary Dubin, Vice President and Director, Late Clinical Development at GlaxoSmithKline Biologicals commented: “We would like to express our gratitude towards our partner NIAID for their proactive collaboration and substantial contribution in the program and the volunteers for their participation in the study.”
The decision was made following receipt of the results of the Herpevac Trial for Women, a Phase III trial evaluating efficacy of Simplirix™, which was conducted collaboratively with the US National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH).
The trial began in 2002 and 8,323 women ages 18-30 were vaccinated at 50 sites in the United States and Canada. An assessment of the final trial results showed that the vaccine had an acceptable safety profile, but the primary trial endpoint, prevention of genital herpes disease, was not met. GSK and NIH continue to evaluate data from the trial and plan to present details of the analysis in the near future in an appropriate scientific forum.
Gary Dubin, Vice President and Director, Late Clinical Development at GlaxoSmithKline Biologicals commented: “We would like to express our gratitude towards our partner NIAID for their proactive collaboration and substantial contribution in the program and the volunteers for their participation in the study.”
Subscribe to:
Posts (Atom)